News
Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder
Nature ·
The Brief
- A Nature Medicine article raises concerns about the use of placebo control in clinical trials of obinutuzumab for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (NMOSD).
- The source feed provided only the headline and no summary, so the specific concerns raised are not available from the sources.
Why it matters
Trial design choices, such as whether to use a placebo control, shape how treatment effects are judged in rare neuroimmune diseases like NMOSD.
Who’s affected
- neurologists and clinical trial researchers
- people with NMOSD and their clinicians
- #neuromyelitis optica
- #clinical trials
- #placebo control
- #obinutuzumab
- #neurology